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Abstract
Our human model of nasal colonization and eradication of S. aureus is limited by safety
issues. As rhesus macaques are closely related to humans and natural hosts for S. aureus,
we developed an experimental decolonization and inoculation protocol in these animals.
Animals were screened for nasal carriage of S. aureus and 20 carriers were selected. Decol-
onization was attempted using nasal mupirocin (10 animals) or mupirocin plus trimethoprim/
sulfadiazine intramuscularly (10 animals) both once daily for 5 days, and checked by follow-
up cultures for 10 weeks. Intranasal inoculation was performed with S. aureus strain 8325–4
in culture-negative animals. 11/20 animals, of which 5 received mupirocin and 6 the combi-
nation treatment, became culture-negative for S. aureus for 10 weeks and these 11 animals
were subsequently inoculated. Swabs were taken once a week for 5 weeks to test for the
presence of the inoculated strain. In 3 animals, strain 8325–4 was cultured from the nose 1
week after inoculation, indicating short-term survival of this strain only, a finding similar to
that previously found in our human model. These data demonstrate that rhesus macaques
may constitute a relevant animal model to perform S. aureus eradication and inoculation
studies with relatively limited invasive handling of the animals.
Introduction
It is well established that Staphylococcus aureus (S. aureus) carriage increases the risk of
endogenous infections with this bacterium [1, 2]. Bode et al. showed that eradication of S.
aureus from the nose and skin significantly decreases the risk of endogenous infections in a
hospital setting [3]. Many different (methicillin-resistant and susceptible) S. aureus eradica-
tion and decolonization strategies have been described. Variations in these treatments are
made based on the presence of clinically evident infection [4]. To further improve our under-
standing of human S. aureus nasal colonization and to support the development of new
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decolonization strategies additional well-designed experiments are needed. Although we
have performed human nasal inoculation studies in our group [5–9], for ethical and safety
reasons these experiments are restricted to a conformational setup while more exploratory
designs are often desired. Therefore, animal models of S. aureus carriage are needed and
some have been presented in the literature. Ideally, an animal model closely mimics the
human condition, in this case requiring the animal to be a natural host of S. aureus and to be
evolutionary closely related to humans. Furthermore, (de) colonization is best studied over a
period of time in which at different time points of follow-up samples can be taken from the
same animal. In one model the cotton rat requires relatively high inocula (1107 to 1109
CFU) in order to establish nasal colonization [10–12]. In addition, animals need to be sacri-
ficed at pre-specified intervals in order to determine bacterial colonization. Thus, bacterial
and host factors interfering with colonization cannot be studied longitudinally as for each
time-point separate groups of animals are included [10–12]. The same limitations apply for
mouse models [13, 14]. Successful S. aureus colonization has been realized in pigs, but only
in piglets delivered by Caesarean section and deprived of colostrum [15, 16]. In addition to
research regarding determinants of colonization, S. aureus decolonization strategies have
also been studied in mice and cotton rats, but we are confronted with the same limitations
[17–19]. Recently, rhesus macaques (Macaca mulatta) were added to the list of natural hosts
of S. aureus [20] making them potentially an ideal human-like model to study S. aureus (de)
colonization.
Therefore, in this study we explored the possibility to develop an experimental decoloniza-
tion and inoculation procedure in rhesus macaques. To do so, we applied two decolonization
strategies; both used in humans, and investigated their potential to decolonize the nares of rhe-
sus macaques carrying S. aureus in their nares. In addition, we studied the possibility to colo-
nize rhesus macaques with a human S. aureus strain.
Materials and methods
Study setup
Rhesus macaques were screened for S. aureus nasal carriage and carriers were included (defini-
tion below). The study design had two phases: in phase 1 S. aureus decolonization with two dif-
ferent treatment strategies was performed, followed by phase 2 in which nasal inoculation with
a human S. aureus strain was attempted.
Animal study population
Animals were selected from the macaque-breeding colony of the Biomedical Primate Research
Centre Rijswijk, the Netherlands. They were born and raised at the institute and remained in
their natal groups for at least 4 years before being selected for research protocols. All animals
received a complete physical, haematological and biochemical examination before inclusion
and were social-housed (pair or trio) for at least 3 weeks before the onset in 3 animal rooms.
Physical contact with other rhesus macaques from the same experimental group in neighbor-
ing cages was possible. In each room the cages were located in two rows opposite to each
other. Because of welfare some of the animals were placed with their buddy rhesus macaque
during phase 1 and 2. A buddy rhesus macaque was not screened for S. aureus nasal carriage
but it did receive the same decolonization treatment as its S. aureus carrier cage mate. Their
culture results were not included in the study.
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Ethical considerations
All animals were socially housed in cages measuring at least 3.6 m3 (2x1.8x1 m) in line with
the size requirements of EU Directive 2010/63. Cages were provided with bedding and food
and non-food enrichment items. Water was provided ad libitum. The animals were fed com-
mercial monkey pellets (Ssniff, Soest, Germany) supplemented with a variation of bread, vege-
tables and fruit. All experimental procedures with the animals were performed under sedation
with 10-mg/kg ketamine. The study protocol was approved by the Animal Ethics Committee
of the Biomedical Primate Research Centre (BPRC) Rijswijk, The Netherlands (DEC #706).
Sampling procedures
The nose was sampled by swabbing both the left and right anterior nares with a single swab
(Amies charcoal transport swabs orange, Copan, CA, USA). Throat and rectal swabs (Amies
charcoal transport swabs black, Copan, CA, USA) were taken respectively by swabbing the
back of the pharynx and by revolving a swab 2 cm into the rectum. The swabs were plated on
Colombia 5% sheep blood agar (OXOID, Hampshire, UK) within a few hours. Plates were
screened for S. aureus suspected colonies based on morphology after 24 and 48 hours of incu-
bation at 35˚C. Final identification of S. aureus was performed by a latex slide agglutination
test that detects clumping factor and Protein A (Staphytect Plus, OXOID, Hampshire, UK).
Susceptibility of the S. aureus strains isolated from the rhesus macaques
The VITEK 2 system (bioMe´rieux) was used for susceptibility testing. The S. aureus strains
were picked randomly and had to originate from the nose from day 0 of the decolonization
phase. S. aureus colonies were suspended in 0.9% saline (NaCl) to make a 0.5 McFarland
(McF) bacterial suspension. Susceptibility card AST-P633 was used for staphylococci. This
card contained benzylpenicillin, oxacillin, gentamicin, kanamycin, tobramycin, ciprofloxacin
translated to levofloxacin, erythromycin, clindamycin, linezolid, teicoplanin, vancomycin, tet-
racycline, fosfomycin, fusidic acid, mupirocin, chloramphenicol, rifampicin and trimetho-
prim/sulfamethoxazole.
S. aureus strain for inoculation
For the inoculation procedure we selected human strain 8325–4 (spa type 211; ST8) [21]
which was previously used in human nasal inoculation studies [5, 8]. Bacteria grown overnight
on Colombia 5% sheep blood agar were used to inoculate Brain Heart Infusion broth (BHI).
After a few hours of growth at 37˚C an OD of 0.5 McF was achieved. The pellet of bacterial cul-
ture was suspended in Phosphate Buffered Saline (PBS) to get the inoculum of 2108 CFU/ml.
50 microliters of this amount of bacteria in PBS contained 1107 CFU of bacterial cells.
Screening and decolonization protocol
Taking 4–5 nasal swabs with intervals of one week, determined the nasal carriage state for S.
aureus. Nasal carriers of S. aureus were defined as animals with four swabs (80%) culture-
positive for S. aureus. Only carriers were included. Two different treatment strategies were
used for decolonization. One treatment consisted of mupirocin nasal ointment (2%; Glaxo-
SmithKline, Waltham, MA, USA) once daily for a total period of 5 days (treatment A). The
other treatment consisted of a combination of mupirocin nasal ointment once daily with 18
mg/kg trimethoprim/sulfadiazine (40 mg/ml/200 mg/ml; Duphatroxim, Zoetis, NL) intramus-
cular injections once daily for a total period of 5 days (treatment B). The mupirocin nasal oint-
ment was applied in the vestibulum nasi with a swab (Heinz Herenz sterile cotton swab).
An experimental model in rhesus macaques
PLOS ONE | https://doi.org/10.1371/journal.pone.0194718 April 12, 2018 3 / 11
Trimethoprim/sulfadiazine was injected alternately into the left and right vastus lateralis. The
study was performed in two different time periods in which the animals were equally divided
over the two treatment regimens. In the follow-up period of 9 weeks a total of 9 (including
t = 0, before start of the treatment) nasal, throat and rectal swabs were taken to investigate
recolonization with S. aureus. More specifically, on day 0, 3 or 4, 7, 9, 14, 21, 35, 49 or 50 and
63 swabs were taken from the three culture sites.
Inoculation protocol
Nasal inoculation was only performed in animals successfully decolonized. Noses of animals
were inoculated 7 days after the last follow-up culture moment from phase 1. As S. aureus
nasal carriage was an exclusion criterion for further follow-up after inoculation, a control swab
was taken from all culture sites on the day of inoculation. 50 microliters of the inoculum con-
taining 1107 CFU of bacterial cells was pipetted separately into the left and right nostril while
the head was put for two minutes in such a position that the inoculum could be absorbed by
the mucosa. In the follow-up period the nose, throat and rectum were cultured in week 1, 2, 3
and 5. For identification of strain 8325–4 after inoculation, all cultured S. aureus strains
obtained in the follow-up period from the inoculation phase, were analyzed by PCR analysis of
the spa gene [22].
Hygiene protocol
To prevent any S. aureus acquisition from environmental, human or animal origin during
both phases of the study, a hygiene protocol was implemented. Before entering the animal
room personnel had to wear non-sterile gloves (Kimtech) and a new gown including a hood
(Tyvek). After entering the room gloves were immediately disinfected with alcohol 70%. Care
was taken to handle first the animals included in the study to prevent possible spread of S.
aureus from animals that were not included. During the five consecutive days of sedation in
the decolonization phase, the animals received 100 ml Nutrison Concentrated Food 2.0 kcal/
ml through a gastric tube to prevent malnutrition. Non-food enrichment was cleaned with
alcohol before rotation and bedding was replaced twice a week. For activities like contact with
every separate cage animal caretakers disinfected their hands. Finally, keys were put in a bath
with alcohol 70% to limit contamination.
Statistical analysis
Recurrence, defined as the first occasion when S. aureus was isolated again after decoloniza-
tion, was analyzed starting from day 7 after start of the decolonization. Recurrence was deter-
mined in either nose only, other sites than the nose or any site, i.e. nose, throat and/or rectum.
Results were analyzed using Kaplan-Meier curves.
Results
Screening and decolonization
A total of 97 rhesus macaques were selected from the BPRC colony and their S. aureus carriage
status was determined. 20 out of 73 rhesus macaques that were at least once positive for S.
aureus in the nose were found to be nasal S. aureus carriers. In total 9 buddies participated.
Divided over 13 cages, 3 animals were triple-housed and the others were pair-housed. 10 rhe-
sus macaques received treatment A (3 females, 7 males) and the others received treatment B (3
females, 7 males). Follow-up cultures were taken from the nose, throat and rectum.
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Individual culture results from the start of both treatments including the follow-up period
are shown in S1 Table. In the group that received treatment A, 2 animals (R10024 and R10122)
were negative in the nose at day 0 and they were therefore excluded from analysis. For com-
pleteness, culture results from the buddy rhesus macaques were analyzed and added in this
table. The results show in most cases variable carriage rates on the three culture sites in the dif-
ferent animals during follow-up. No specific carriage patterns were seen in the individual rhe-
sus macaques except for some animals in which throat carriage was more persistent over time
than in the other animals. Furthermore, cage mates were seldom carrier at the same culture
site at the same culture moment (S1 Table).
In animals that received mupirocin only (treatment A) no S. aureus was cultured from the
nose in any of the animals from day 7–21. S. aureus was observed in one animal after 21 days
but all animals were once more negative in the following culture moment at day 35. From day
49 after the treatment 2 animals were again colonized with S. aureus in the nose (S1A Fig). In
this treatment group a rapid decline in S. aureus throat and rectum carriage to 0% was
observed within the first nine days. In some animals recolonization occurred from day 14 until
the end of the follow-up period (S1 Table, S1B Fig).
S. aureus was eradicated from the noses of all animals that received mupirocin and trimeth-
oprim/sulfadiazine (treatment B) from day 7–21 after the start of treatment. On day 35 and 49,
2 animals were positive in the nose for S. aureus and this number increased to 4 at the end of
the follow-up period (S1A Fig). Throat carriage rates after treatment B declined from 7 animals
to 1 in the first 9 days. In the remaining follow-up period S. aureus throat carriage varied
between 3 and 4 animals. Finally, at the start of treatment B, 1 animal was positive in the rec-
tum for S. aureus and during the follow-up carriage on this site was at most found in 1 animal
(S1 Table, S1B Fig).
There was no difference between the treatment groups when the portion of animals positive
for S. aureus was determined for nose only, other sites than the nose or any site. In addition,
the first occasion when S. aureus was cultured after decolonization was analyzed using Kaplan-
Meier curves for either nose only (Fig 1A), other sites than the nose (Fig 1B) or any site, i.e.
nose, throat and/or rectum (Fig 1C). The data demonstrate that there is no difference between
the two treatments with respect to the time that in some animals the nose became positive.
Even after 63 days 60% of all animals from both treatment groups were negative in the nose
(Fig 1A). However, when throat or rectum were analyzed separately or any site, more animals
became positive again and a trend was seen suggesting that in the animals that received treat-
ment B the time to become positive was longer than in animals that received treatment A (Fig
1B and 1C). This trend is not statistically significant because this study concerned a proof-of-
principle study for decolonization and it was not powered for the statistical detection of this
difference.
Inoculation
A total of 11 animals never became positive for S. aureus in the nose during the follow-up
period of 63 days (S1 Table). Of these 11 animals, 5 had received treatment A and 6 had
received treatment B. Animals were inoculated with human S. aureus strain 8325–4. 2 rhesus
macaques were found to be positive for S. aureus in the nose on the day of inoculation and
they were excluded from further analyses. Follow-up cultures were taken from nose, throat
and rectum in week 1, 2, 3 and 5. In 3/9 animals remaining in the experiment, the inoculated
S. aureus strain 8325–4, was found in the nose one week after inoculation. 2 of these animals
had received treatment B and the other animal treatment A. The successive follow-up cultures
on all culture sites became negative in these 3 animals. In the other 6 animals strain 8325–4
An experimental model in rhesus macaques
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Fig 1. Kaplan-Meier curves. The proportion of S. aureus positive animals is represented by a continuous (treatment
A) or dotted (treatment B) line. Fig 1A, 1B and 1C show respectively results from nose only, other sites than nose and
any site.
https://doi.org/10.1371/journal.pone.0194718.g001
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was never cultured but in 3 of them S. aureus other than 8325–4 was cultured in the throat and
in 1 also in the rectum.
Susceptibility of the S. aureus strains isolated from the rhesus macaques
For susceptibility testing 10 S. aureus strains were used. These strains were derived from the
nasal cavities of 10 different animals. All strains were susceptible to all the antimicrobials that
were tested, including mupirocin and trimethoprim/sulfamethoxazole.
Discussion
To our knowledge this is the first study in which a controlled experimental S. aureus nasal
decolonization and inoculation model in rhesus macaques is presented. With the standardized
protocols the noses of carriers were successfully decolonized for a period of 10 weeks or more.
We tested 2 S. aureus decolonization strategies, a topical treatment with mupirocin nasal oint-
ment and a combination treatment of mupirocin nasal ointment with systemic trimethoprim/
sulfadiazine. There was no significant difference between the two treatments as almost all ani-
mals became negative for S. aureus in the nose, throat and rectum and in both groups compa-
rable numbers of animals became positive again. Also with respect to time of first recurrence
of S. aureus, there was no difference between the two treatment groups when only the nose
was analyzed. However, analysis of recurrence of S. aureus at any site showed a trend suggest-
ing that treatment B was more effective than treatment A.
The two different treatment strategies for decolonization of nasal carriers were based on the
eradication strategies for complicated and uncomplicated MRSA carriage in humans. Uncom-
plicated carriage implies nasal colonization only and complicated carriage is defined as nasal
colonization in combination with one or more of the following criteria: extra-nasal carriage
sites, or a clinically active infection, or the presence of skin lesions, foreign-body material, or
the finding of mupirocin resistance in the colonizing strain. For uncomplicated carriage
mupirocin nasal ointment and chlorhexidine-containing body wash is recommended for
humans. In complicated S. aureus carriers this topical treatment regimen is augmented with
systemic antimicrobials [4].
In both protocols used in this study we did not add chlorhexidine-containing body washes
because of two practical reasons: the large amount of body hair of these animals was thought
to limit the effectiveness of skin decolonization and body washes would require additional
periods of anesthesia which would increase the risk of complications. A systemic intramuscu-
larly injectable antimicrobial trimethoprim/sulfadiazine was chosen because it is registered in
veterinary medicine in the Netherlands whereas cotrimoxazole (trimethoprim/sulfamethoxa-
zole), commonly used in human medicine, does not guarantee optimal oral uptake in animals.
Furthermore, Ammerlaan et al. recommended to always using a combination of two systemic
antimicrobials to eradicate S. aureus, and to choose an antimicrobial combination that
included either fusidic acid or rifampicin [4]. However, these latter two antimicrobials are not
registered in veterinary medicine and were therefore, not considered for this series of experi-
ments. In order to limit the number of sedations we administered both treatments once daily.
Our data indicate that (un) complicated S. aureus carriage in rhesus macaques can well be
eradicated with topical applied mupirocin alone, the addition of systemic trimethoprim/sulfa-
diazine did not enhance decolonization.
Although we were able to inoculate the noses of the rhesus macaques with human S. aureus
strain 8325–4, we did not observe stable long-term colonization with this strain. Though, in
previous studies, S. aureus 8325–4 was shown to persist for at least 4 weeks in the human nose
despite the presence of a defect in the sigma factor (SigB) locus [5, 8, 23]. By choosing this
An experimental model in rhesus macaques
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strain we had the benefit to be able to use our previous experience in human inoculation
experiments as a starting point. Furthermore, 8325–4 is suitable for genetic modification and
can be applied for both knockout [5, 8] and knock-in studies. On the contrary, by selecting
8325–4 we took the risk on poor colonization, yet we wanted to investigate if we could use a
human strain to inoculate a rhesus macaque. Our data show that 8325–4 presumably is not the
ideal strain to work with in the rhesus macaque model. In a preceding study we have shown
that rhesus macaques are naturally colonized with S. aureus strains that have genetically differ-
ent backgrounds from human strains of this species [20]. Therefore, in future experiments,
selecting a strain from the collection of S. aureus cultured from rhesus macaque (persistent)
carriers might show to be a better take.
In addition to natural variation in nasal microflora, an alternative explanation for our lim-
ited success in the colonization phase of the study could be the method we used to apply the
inoculum. In earlier human inoculation experiments 1107 CFU were applied in the nose with
a swab [5–9] but the (smaller) nasal anatomy of rhesus macaques does not allow to use the
same swab as used in humans. Therefore, we had to adapt the inoculation procedure, which
might have resulted in loss of part of the bacterial inoculum due to swallowing. Although, in
the cotton rat model the same inocula and method of instillation are used for nasal inoculation
experiments, in the rat it seems more successful than in our rhesus macaque model in compa-
rable periods of follow-up. Possibly, this is due to the fact that, after sacrificing the rats, noses
are completely removed and then homogenized which might result in better recovery of the
bacteria from the nose [10–12]. A third possible explanation could be that mupirocin was still
active at the time of inoculation. Fernandez et al. studied the efficacy of mupirocin on S. aureus
nasal colonization in which recolonization after 2–4 months was seen in 56% of the study pop-
ulation [24]. On the contrary, our human model [5–9] showed successful inoculation 6 weeks
after decolonization with mupirocin and chlorhexidine-containing body wash. Nevertheless,
we showed that we were able to inoculate the noses of some of the rhesus macaques for at least
one week.
Concerning nasal S. aureus carriage, animals were swabbed 4–5 times with intervals of one
week. We defined carriage as animals in which at least 80% of the nasal cultures had to be S.
aureus positive. Our definition is in line with the definition of (persistent) carriage used in sev-
eral publications of human studies. However, in some publications additional criteria are
defined which are related to the number of consecutive swabs that have to be taken, the num-
ber of CFU/swab but also the added value to test for genetic background [9, 25–28]. While
many variations in definition exist, for this study we elected to stick to one that is practical and
commonly used in literature.
During the development of this model we were confronted with a couple of issues. Two ani-
mals were culture-negative for S. aureus in the nose on the day of start of the treatments. These
animals were already classified as nasal carriers, so this result required exclusion. It is apparent
that in macaques, as in humans, carriage rate and densities, although we did not culture quan-
titatively, are prone to some variation over time, which was also seen in the follow-up period
after treatment A and B, especially for the extra-nasal culture sites. We observed very low car-
riage rates in the rectum, which could be a result of our culture conditions. S. aureus could
have been overgrown by gram negative bacteria from the gut so maybe a selective agar would
have been a better choice. Another, the throat in particular, was alternately positive in most of
the animals. Recognition of this phenomenon should be acknowledged when designing,
implementing and interpreting studies on decolonization.
Another finding, albeit not a focus in this study, concerned the transmission of S. aureus.
Mollema et al. showed that (human) household members have a risk of 47% to transmit S.
aureus when one of them is positive [29]. In our study we showed that some monkeys
An experimental model in rhesus macaques
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including the buddies never acquired any S. aureus in the follow-up period while S. aureus was
present in their cage mate. Also, some animals were positive for S. aureus at a specific carrier
site while the cage mate was a carrier at another site. Since we did not type these strains it is
unknown whether transmission of S. aureus had occurred or not. Finally, we used spa typing,
which is less delicate than for example whole genome sequencing but it served its purpose of
identifying strain 8325–4.
In conclusion, this model can be used for S. aureus decolonization and inoculation studies
in a properly controlled fashion. In contrast to small animal models, this model is attractive
since this species of animals allows for long-term follow-up of the carrier state in individual
subjects, and does not require animals to be sacrificed as part of the experimental protocol.
Moreover, macaques are natural carriers of S. aureus and are closely related to humans, which
makes them also attractive to study host-pathogen interaction.
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